FDA Class II Recall: Golden State Medical Supply's Budesonide Extended-Release Tablets Fail Dissolution Specifications
Golden State Medical Supply Inc. initiated a Class II recall for 108 bottles of Budesonide Extended-Release Tablets, 9 mg, due to failed dissolution specifications. This voluntary, firm-initiated action, impacting only Illinois, was terminated on March 20, 2025. Procurement and regulatory teams should note the specific quality deviation and its resolution, though the limited distribution minimizes broader supply chain disruption.
FDA Class II Recall Initiated by Golden State Medical Supply for Budesonide Extended-Release Tablets
On January 12, 2024, Golden State Medical Supply Inc. (GSMS), based in Camarillo, CA, initiated a voluntary Class II recall, designated D-0276-2024, for its Budesonide Extended-Release Tablets, 9 mg. This critical action stemmed from the product's failure to meet dissolution specifications, a fundamental quality attribute for drug performance. The recall specifically targeted 108 bottles from Lot #: GS054862, with an expiration date of July 31, 2025. Each bottle contained 30 tablets and was marketed under NDC 51407-824-30 and UPC 5140782430. For procurement directors and regulatory affairs heads, this event underscores the paramount importance of dissolution testing, particularly for extended-release formulations like Budesonide. A failure in dissolution means the active pharmaceutical ingredient (API) may not be released from the tablet at the intended rate or extent, directly impacting drug efficacy and potentially leading to sub-therapeutic levels or, conversely, dose dumping. This poses significant risks to patient safety and therapeutic outcomes, especially for a drug like Budesonide used in conditions requiring controlled release. Businesses must ensure their quality agreements with suppliers include stringent dissolution testing protocols and robust out-of-specification (OOS) investigation procedures to mitigate such risks and maintain product integrity.
Limited Geographic Scope and Supply Chain Implications for Budesonide Procurement
The distribution pattern for the recalled Budesonide Extended-Release Tablets was explicitly limited to Illinois only. This narrow geographical scope significantly curtails the immediate supply chain disruption for procurement directors and supply chain VPs operating outside this specific state. While any recall signals a quality system vulnerability, the contained distribution footprint means that the broader market for Budesonide, a corticosteroid used to treat conditions like Crohn's disease, remains largely unaffected by this particular event from Golden State Medical Supply Inc. However, this incident still serves as a crucial reminder for supply chain executives to scrutinize the full manufacturing and distribution network of their pharmaceutical products. The product description notes it was "Marketed by: GSMS, Incorporated," which often implies the actual manufacturing may occur at a different facility or by a contract manufacturing organization (CMO). This distinction necessitates a thorough understanding of the entire supply chain, from API sourcing to final product distribution, to identify all potential points of failure. Business development executives should leverage such events to assess the resilience and transparency of their own supply chains, ensuring that quality oversight extends beyond direct suppliers to all entities involved in product realization, regardless of the limited initial impact.
Recall Termination and Broader Regulatory Compliance Landscape
The FDA officially classified this recall as Terminated on March 20, 2025, indicating that Golden State Medical Supply Inc. has completed all necessary actions to remove the affected product from the market and address the root cause of the dissolution failure. For regulatory affairs heads, the termination status provides assurance that the immediate risk associated with this specific lot of Budesonide Extended-Release Tablets has been resolved. However, it does not absolve the firm, or any company, from ongoing regulatory scrutiny regarding their quality management systems and adherence to current Good Manufacturing Practices (cGMP). This event, while specific to dissolution failure, occurs within a broader industry context where quality control challenges are persistent. Recent parallel events highlight diverse issues, such as Pfizer's Class I recalls for Bleomycin and Sodium Bicarbonate Injections due to glass particulate matter, and Class II recalls by Sandoz and Teva Pharmaceuticals for Enoxaparin Sodium and Warfarin Sodium, respectively, citing temperature excursion risks and storage deviations. These incidents, though unrelated to Golden State Medical Supply or Budesonide, collectively emphasize that robust quality assurance, from manufacturing to distribution, remains a critical and continuous imperative across the global chemical and life sciences industry. Business development executives must integrate this understanding into their strategic planning, prioritizing partners with impeccable compliance records to safeguard product quality and market access.